Biomarker & Intervention Discovery
Chronic Lymphocytic Leukaemia (CLL)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionEarly-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to…
Best-intervention remissionVenetoclax + obinutuzumab (CLL14): 2-year fixed duration, MRD-undetectable remission in 36%, PFS benefit sustained at…
Gap sizeLarge — chlorambucil still used in some elderly patients; BTK inhibitor choice and venetoclax combination timing are…
Primary barrierpractice/access
Full remission profile →
Remission & chronicity
Spontaneous remission
Early-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to treatment in Rai Stage 0: 10+ years; Richter's transformation (5-10%) extremely poor prognosis
Best-intervention remission
Venetoclax + obinutuzumab (CLL14): 2-year fixed duration, MRD-undetectable remission in 36%, PFS benefit sustained at 5 years vs chlorambucil; ibrutinib continuous: PFS benefit but not curative; BRUIN CLL trial (pirtobrutinib): 73% ORR in ibrutinib-resistant CLL
Gap size
Large — chlorambucil still used in some elderly patients; BTK inhibitor choice and venetoclax combination timing are practice-variable
Primary barrier
practice/access
Chemoimmunotherapy (FCR, BR) largely replaced by BTK inhibitors and venetoclax but chlorambucil still used where cost is a barrier; the 'best drug at first relapse' question is evolving rapidly; CAR-T not yet standard for CLL
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Chronic Lymphocytic Leukaemia (CLL)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."